Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Butler, Joseph S ^a,b   Queally, Joseph M ^a,b   Devitt, Brian M ^a,b   Murray, David W ^a   Doran, Peter P ^a   O'Byrne, John M ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b CAPPAGH NATIONAL ORTHOPAEDIC HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; DEXAMETHASONE; DICKKOPF 1 PROTEIN; SMALL INTERFERING RNA; WNT PROTEIN; DKK1 PROTEIN, HUMAN; GROWTH INHIBITOR; SIGNAL PEPTIDE;

ARTICLE; CELL DIFFERENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OSTEOBLAST; PROTEIN EXPRESSION; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PHYSIOLOGY;

CELL DIFFERENTIATION; CELLS, CULTURED; DEXAMETHASONE; GENE EXPRESSION REGULATION; GENE SILENCING; GROWTH INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOBLASTS;

EID: 77956498721     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-210     Document Type: Article

References (33)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis Therapy, JAMA 2001 285 6 785 95 10.1001/jama.285.6.785 11176917
2. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. CJ Hurson JS Butler DT Keating DW Murray DM Sadlier JM O'Byrne PP Doran, BMC Musculoskelet Disord 2007 8 12 10.1186/1471-2474-8-12 17295923
3. The promise and perils of Wnt signaling through beta-catenin. RT Moon B Bowerman M Boutros N Perrimon, Science 2002 296 1644 6 10.1126/science.1071549 12040179
4. Increasingly complex: new players enter the Wnt signaling network. P Pandur D Maurus M Kuhl, Bioessays 2002 24 10 881 4 10.1002/bies.10164 12325120
5. The Wnt signaling pathway in development and disease. CY Logan R Nusse, Annu Rev Cell Dev Biol 2004 20 781 810 10.1146/annurev.cellbio.20.010403.113126 15473860
6. The Wnts. JR Miller, Genome Biol 2002 3 1 EVIEWS3001 Epub 2001 Dec 28 11806834
7. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. YQ Gong RB Slee N Fukai G Rawadi S Roman-Roman AM Reginato, et al. Cell 2001 107 513 23 10.1016/S0092-8674(01)00571-2 11719191
8. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. YQ Gong M Vikkula L Boon J Liu P Beighton R Ramesar, et al. Am J Hum Genet 1996 59 146 51 8659519
9. High bone density due to a mutation in LDL-receptor-related protein 5. LM Boyden JH Mao J Belsky L Mitzner A Farhi MA Mitnick, et al. N Engl J Med 2002 346 1513 21 10.1056/NEJMoa013444 12015390
10. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. RD Little JP Carulli RG Del Mastro J Dupuis M Osborne C Folz, et al. Am J Hum Genet 2002 70 11 9 10.1086/338450 11741193
11. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. L Van Wesenbeeck E Cleiren J Gram RK Beals O Benichou D Scopelliti, et al. Am J Hum Genet 2003 72 763 71 10.1086/368277 12579474
12. WNT and beta-catenin signalling: diseases and therapies. RT Moon AD Kohn GV De Ferrari A Kaykas, Nat Rev Genet 2004 5 9 691 701 10.1038/nrg1427 15372092
13. Regulation of bone mass by Wnt signaling. V Krishnan HU Bryant OA Macdougald, J Clin Invest 2006 116 5 1202 9 10.1172/JCI28551 16670761
14. Wnt signaling: a key regulator of bone mass. R Baron G Rawadi S Roman-Roman, Curr Top Dev Biol 2006 76 103 27 10.1016/S0070-2153(06)76004-5 17118265
15. Wnt signaling in osteoblasts and bone diseases. JJ Westendorf RA Kahler TM Schroeder, Gene 2004 341 19 39 10.1016/j.gene.2004.06.044 15474285
16. Wnt signaling as a therapeutic target for bone diseases. LH Hoeppner FJ Secreto JJ Westendorf, Expert Opin Ther Targets 2009 13 4 485 96 10.1517/14728220902841961 19335070
17. Wnt signaling and potential applications in bone diseases. G Rawadi, Curr Drug Targets 2008 9 7 581 90 10.2174/138945008784911778 18673244
18. LRP5 and Wnt signaling: a union made for bone. ML Johnson K Harnish R Nusse W Van Hul, J Bone Miner Res 2004 19 11 1749 57 Epub 2004 Aug 23 10.1359/JBMR.040816 15476573
19. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). W Balemans M Ebeling N Patel E Van Hul P Olson M Dioszegi, et al. Hum Mol Genet 2001 10 5 537 43 10.1093/hmg/10.5.537 11181578
20. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. K Staehling-Hampton S Proll BW Paeper L Zhao P Charmley, et al. Am J Genet 2002 110 2 144 52 10.1002/ajmg.10401 (Pubitemid 34569019)
21. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. A Bafico GZ Liu A Yaniv A Gazit SA Aaronson, Nat Cell Biol 2001 3 683 6 10.1038/35083081 11433302
22. Kremen proteins interact with Dickkopf1 to regulate anteroposterior CNS patterning. G Davidson BY Mao ID Barrantes C Niehrs, Development 2002 129 5587 96 10.1242/dev.00154 12421700
23. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. CA Gregory H Singh AS Perry DJ Prockop, J Biol Chem 2003 278 28067 78 10.1074/jbc.M300373200 12740383
24. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. EY Chu J Hens T Andl A Kairo TP Yamaguchi C Brisken, et al. Development 2004 131 4819 29 10.1242/dev.01347 15342465
25. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. F Kuhnert CR Davis HT Wang P Chu M Lee J Yuan, et al. Proc Natl Acad Sci USA 2004 101 266 71 10.1073/pnas.2536800100 14695885
26. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. XF Li P Liu WZ Liu P Maye JH Zhang YH Zhang, et al. Nat Genet 2005 37 945 52 10.1038/ng1614 16056226
27. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. E Tian FH Zhan R Walker E Rasmussen YP Ma B Barlogie, et al. N Engl J Med 2003 349 2483 94 10.1056/NEJMoa030847 14695408
28. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. J Li I Sarosi RC Cattley J Pretorius F Asuncion M Grisanti, et al. Bone 2006 39 4 754 66 Epub 2006 May 26 10.1016/j.bone.2006.03.017 16730481
29. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. F Morvan K Boulukos P Clément-Lacroix S Roman Roman, et al. J Bone Miner Res 2006 21 6 934 45 10.1359/jbmr.060311 16753024
30. Bone mass is inversely proportional to Dkk1 levels in mice. BT MacDonald DM Joiner SM Oyserman P Sharma SA Goldstein, et al. Bone 2007 41 3 331 9 Epub 2007 Jun 5 10.1016/j.bone.2007.05.009 17613296
31. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. FS Wang JY Ko DW Yeh HC Ke HL Wu, Endocrinology 2008 149 4 1793 801 Epub 2008 Jan 3 10.1210/en.2007-0910 18174290
32. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. K Ohnaka H Taniguchi H Kawate H Nawata R Takayanagi, Biochem Biophys Res Commun 2004 318 1 259 64 10.1016/j.bbrc.2004.04.025 15110782
33. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. K Ohnaka M Tanabe H Kawate H Nawata R Takayanagi, Biochem Biophys Res Commun 2005 329 1 177 81 10.1016/j.bbrc.2005.01.117 15721290